292 related articles for article (PubMed ID: 15374944)
1. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
4. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Heidel F; Solem FK; Breitenbuecher F; Lipka DB; Kasper S; Thiede MH; Brandts C; Serve H; Roesel J; Giles F; Feldman E; Ehninger G; Schiller GJ; Nimer S; Stone RM; Wang Y; Kindler T; Cohen PS; Huber C; Fischer T
Blood; 2006 Jan; 107(1):293-300. PubMed ID: 16150941
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
6. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
8. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
9. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Levis M; Tse KF; Smith BD; Garrett E; Small D
Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
[TBL] [Abstract][Full Text] [Related]
10. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
11. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
12. FLT3 Inhibitors in the Treatment of AML.
Gilliland DG
Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
[No Abstract] [Full Text] [Related]
13. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
Martinelli G; Piccaluga PP; Lo Coco F
Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
[No Abstract] [Full Text] [Related]
17. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
[TBL] [Abstract][Full Text] [Related]
18. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
19. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
[TBL] [Abstract][Full Text] [Related]
20. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
